Therapy With Immunoglobulin Suppresses Myocarditis in a Murine Coxsackievirus B3 Model
- 15 September 1995
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 92 (6) , 1604-1611
- https://doi.org/10.1161/01.cir.92.6.1604
Abstract
Background The treatment of some inflammatory diseases (eg, Kawasaki disease) with immunoglobulin has been demonstrated to be effective. Accordingly, to elucidate the mechanism underlying such actions of immunoglobulin, we examined its effects on murine coxsackievirus B3 (CB3) myocarditis. Methods and Results An in vitro study showed dose-dependent suppression of CB3 by immunoglobulin. Immunoglobulin 1 g · kg−1 · d−1 IP was administered to CB3-infected C3H/He mice daily for 2 weeks, beginning simultaneously with virus inoculation in experiment 1 and on day 14 after virus inoculation in experiment 2. In both experiments, survival was higher in treated than in control mice; at the time of death, inflammatory cell infiltration and the severity of necrosis and calcification also were reduced. Notably, in experiment 1, immunoglobulin administration completely suppressed the development of myocarditis. Serum-neutralizing antibody titers in the treated mice were significantly higher than those in untreated mice in experiment 1 but not in experiment 2. The circulating antibodies of the treated mice were primarily of exogenous origin in experiment 1 and of exogenous and endogenous origins in experiment 2. The analysis of splenic lymphocyte subsets revealed a marked decrease of the B cell population in the treated mice. Conclusions Immunoglobulin therapy completely suppressed acute CB3 myocarditis by transferring the neutralizing antibody into the host in the acute viremic stage and induced an anti-inflammatory effect in the subsequent aviremic stage; the reduction of the splenic B-cell population may be closely associated with an anti-inflammatory effect.Keywords
This publication has 25 references indexed in Scilit:
- Expression of intercellular adhesion molecule-1 in murine hearts with acute myocarditis caused by coxsackievirus B3.Journal of Clinical Investigation, 1993
- Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens [see comment]Journal of Clinical Investigation, 1993
- Intravenous IgG: supertherapy for superantigens?Journal of Clinical Investigation, 1993
- Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model.Journal of Clinical Investigation, 1989
- Reversal of lymphocyte activation in vivo in the Kawasaki syndrome by intravenous gammaglobulin.Journal of Clinical Investigation, 1987
- The Treatment of Kawasaki Syndrome with Intravenous Gamma GlobulinNew England Journal of Medicine, 1986
- Treatment of Refractory Immune Thrombocytopenic Purpura with an Anti-Fcγ-Receptor AntibodyNew England Journal of Medicine, 1986
- Coxsackievirus myocarditis—With special reference to acute and chronic effectsProgress in Cardiovascular Diseases, 1985
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958